Taysha Gene Therapies (TSHA) Competitors $1.28 +0.04 (+2.81%) Closing price 04/14/2025 04:00 PM EasternExtended Trading$1.27 -0.01 (-0.78%) As of 08:26 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock TSHA vs. OCUL, IOVA, SNDX, WVE, COLL, ELVN, DYN, GPCR, ETNB, and CMRXShould you be buying Taysha Gene Therapies stock or one of its competitors? The main competitors of Taysha Gene Therapies include Ocular Therapeutix (OCUL), Iovance Biotherapeutics (IOVA), Syndax Pharmaceuticals (SNDX), Wave Life Sciences (WVE), Collegium Pharmaceutical (COLL), Enliven Therapeutics (ELVN), Dyne Therapeutics (DYN), Structure Therapeutics (GPCR), 89bio (ETNB), and Chimerix (CMRX). These companies are all part of the "pharmaceutical products" industry. Taysha Gene Therapies vs. Ocular Therapeutix Iovance Biotherapeutics Syndax Pharmaceuticals Wave Life Sciences Collegium Pharmaceutical Enliven Therapeutics Dyne Therapeutics Structure Therapeutics 89bio Chimerix Ocular Therapeutix (NASDAQ:OCUL) and Taysha Gene Therapies (NASDAQ:TSHA) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, community ranking, profitability, earnings, dividends, media sentiment, valuation, risk and institutional ownership. Which has more risk and volatility, OCUL or TSHA? Ocular Therapeutix has a beta of 1.49, meaning that its share price is 49% more volatile than the S&P 500. Comparatively, Taysha Gene Therapies has a beta of 0.96, meaning that its share price is 4% less volatile than the S&P 500. Do analysts recommend OCUL or TSHA? Ocular Therapeutix presently has a consensus target price of $16.38, indicating a potential upside of 116.31%. Taysha Gene Therapies has a consensus target price of $6.63, indicating a potential upside of 417.58%. Given Taysha Gene Therapies' stronger consensus rating and higher possible upside, analysts plainly believe Taysha Gene Therapies is more favorable than Ocular Therapeutix.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ocular Therapeutix 0 Sell rating(s) 1 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.89Taysha Gene Therapies 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is OCUL or TSHA more profitable? Taysha Gene Therapies has a net margin of -229.67% compared to Ocular Therapeutix's net margin of -283.74%. Ocular Therapeutix's return on equity of -45.18% beat Taysha Gene Therapies' return on equity.Company Net Margins Return on Equity Return on Assets Ocular Therapeutix-283.74% -45.18% -30.87% Taysha Gene Therapies -229.67%-106.36%-49.16% Does the MarketBeat Community believe in OCUL or TSHA? Ocular Therapeutix received 334 more outperform votes than Taysha Gene Therapies when rated by MarketBeat users. However, 77.70% of users gave Taysha Gene Therapies an outperform vote while only 70.27% of users gave Ocular Therapeutix an outperform vote. CompanyUnderperformOutperformOcular TherapeutixOutperform Votes44270.27% Underperform Votes18729.73% Taysha Gene TherapiesOutperform Votes10877.70% Underperform Votes3122.30% Do institutionals & insiders hold more shares of OCUL or TSHA? 59.2% of Ocular Therapeutix shares are held by institutional investors. Comparatively, 77.7% of Taysha Gene Therapies shares are held by institutional investors. 3.5% of Ocular Therapeutix shares are held by company insiders. Comparatively, 2.7% of Taysha Gene Therapies shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Does the media prefer OCUL or TSHA? In the previous week, Ocular Therapeutix had 10 more articles in the media than Taysha Gene Therapies. MarketBeat recorded 15 mentions for Ocular Therapeutix and 5 mentions for Taysha Gene Therapies. Taysha Gene Therapies' average media sentiment score of 0.70 beat Ocular Therapeutix's score of 0.66 indicating that Taysha Gene Therapies is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ocular Therapeutix 2 Very Positive mention(s) 1 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Taysha Gene Therapies 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has stronger valuation & earnings, OCUL or TSHA? Ocular Therapeutix has higher revenue and earnings than Taysha Gene Therapies. Ocular Therapeutix is trading at a lower price-to-earnings ratio than Taysha Gene Therapies, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOcular Therapeutix$63.72M18.89-$80.74M-$1.26-6.01Taysha Gene Therapies$8.33M31.49-$111.57M-$0.36-3.56 SummaryTaysha Gene Therapies beats Ocular Therapeutix on 9 of the 17 factors compared between the two stocks. Remove Ads Get Taysha Gene Therapies News Delivered to You Automatically Sign up to receive the latest news and ratings for TSHA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TSHA vs. The Competition Export to ExcelMetricTaysha Gene TherapiesBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$262.40M$2.90B$5.35B$7.58BDividend YieldN/A1.91%5.11%4.33%P/E Ratio2.0330.3721.7617.79Price / Sales31.49438.19376.0394.59Price / CashN/A168.6838.1534.64Price / Book3.203.456.443.99Net Income-$111.57M-$72.06M$3.20B$247.24M7 Day Performance13.27%8.22%6.16%6.12%1 Month Performance-25.58%-17.76%-8.82%-7.11%1 Year Performance-51.88%-29.82%9.66%-0.85% Taysha Gene Therapies Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TSHATaysha Gene Therapies2.9577 of 5 stars$1.28+2.8%$6.63+417.6%-56.5%$262.40M$8.33M2.03180OCULOcular Therapeutix3.4165 of 5 stars$6.30-0.9%$16.38+159.9%-5.3%$1.00B$63.72M-4.77230IOVAIovance Biotherapeutics4.2557 of 5 stars$3.03+1.0%$20.25+568.3%-72.4%$993.47M$164.07M-2.03500Analyst ForecastNews CoverageGap DownHigh Trading VolumeSNDXSyndax Pharmaceuticals3.4918 of 5 stars$11.01-2.1%$36.20+228.8%-48.3%$947.34M$23.68M-3.03110Gap DownWVEWave Life Sciences4.1764 of 5 stars$5.80-3.8%$22.60+289.7%+3.4%$890.22M$108.30M-5.23240Short Interest ↑Analyst RevisionGap UpCOLLCollegium Pharmaceutical4.1634 of 5 stars$27.38-2.7%$43.60+59.2%-25.1%$879.77M$631.45M11.80210News CoveragePositive NewsGap DownELVNEnliven Therapeutics2.5493 of 5 stars$17.87-4.4%$38.75+116.8%-18.5%$875.70MN/A-9.4150News CoverageGap DownDYNDyne Therapeutics3.7363 of 5 stars$7.49-9.5%$47.46+533.7%-71.1%$847.28MN/A-2.10100Positive NewsGap UpGPCRStructure Therapeutics2.5622 of 5 stars$14.31-5.4%$81.29+468.0%-51.8%$820.58MN/A-19.34136News CoverageGap UpETNB89bio2.5739 of 5 stars$5.49-4.9%$27.56+401.9%-39.7%$801.45MN/A-1.8940Short Interest ↑News CoverageGap DownHigh Trading VolumeCMRXChimerix2.9049 of 5 stars$8.52-0.1%$8.53+0.2%+788.9%$799.21M$212,000.00-9.0690Positive News Remove Ads Related Companies and Tools Related Companies OCUL Alternatives IOVA Alternatives SNDX Alternatives WVE Alternatives COLL Alternatives ELVN Alternatives DYN Alternatives GPCR Alternatives ETNB Alternatives CMRX Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TSHA) was last updated on 4/15/2025 by MarketBeat.com Staff From Our PartnersElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | Sponsored[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredElon’s Silver Play? Trump Clears the PathNothing is confirmed—yet. But Musk has disrupted every industry he's touched, and Trump's policies make the ti...Priority Gold | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsElon Musk just confirmed Tesla’s robot will go to Mars. But on Earth, it may trigger a trillion-dollar tech sh...InvestorPlace | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTrump Orders 'National Digital Asset Stockpile'‘Digital Asset Reserve’ for THIS Coin??? Get all the details before this story gains even more tractionCrypto 101 Media | SponsoredAmerica’s Retirement Accounts Are at Risk—Here’s WhyWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Taysha Gene Therapies, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Taysha Gene Therapies With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy TSHA Stock Free TSHA Stock Alerts